The discovery of siRNA and its role in RNAi was a groundbreaking finding in the field of molecular biology. In 1998, Andrew Fire and Craig Mello published a seminal paper describing the phenomenon of ...
Cayman Islands, December 17, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven ...
Just as the use of RNA interference has mushroomed throughout the world over the last six years, the number of bioinformatics tools to screen for siRNA has blossomed, too. More than a half-dozen ...
The red-hot field of RNA interference (RNAi) could benefit from patents issued jointly to Queensland, Australia-based Benitec, and the State of Queensland (US patent 6,573,099, issued June 3, 2003, ...
Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...
RNA interference (RNAi) offers a promising approach for AML patients with FLT3-ITD mutations, addressing challenges like drug resistance and high relapse rates. Lipopolymers have demonstrated efficacy ...
RNA interference using small interfering RNAs (siRNAs) has become a mainstay of functional gene characterization and has generated over a dozen FDA-approved therapeutics and drugs in late-stage ...
The study demonstrates that this RNAi approach shuts down vital fungal genes, thereby inhibiting pathogen growth - a groundbreaking step in the development of new antifungal therapies. (Nanowerk News) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback